Pathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Unraveling the role of autoantibodies in rheumatoid arthritis: Toward personalized treatment
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.
What you’ll learn:
- How integrated proteomic and immunological profiling uncovers distinct RA subtypes
- The role of autoantibodies in tracking disease progression and predicting treatment outcomes using KREX™ technology
- New molecular insights into RA pathology and therapeutic targeting opportunities
Whether you’re researching autoimmune mechanisms or exploring novel diagnostics and treatments, this session offers valuable perspectives from the frontlines of proteomics and precision medicine.
Watch now and take the next step in understanding RA at the molecular level.
Allan Stensballe, PhD
Aalborg University
Allan Stensballe is a distinguished researcher in the field of proteomics, focused on elucidating the molecular mechanisms underlying autoimmune disorders like RA. By integrating advanced proteomic technologies – such as nanoproteomics and protein array-based diagnostics – with clinical and immunological data, his pioneering work has significantly advanced personalized medicine by identifying disease biomarkers, exploring the role of the extracellular matrix in RA and informing targeted therapeutic strategies.
Pathways to Digital Health: AI and Omics in Rheumatoid Arthritis
A presentation by Allan Stensballe, PhD
More webinars
WebinarUsing Antibody Profiling to Identify Novel Diagnostic Biomarkers
Current cancer screening methods often lead to false positives, false negatives and invasive biopsies that lack prognostic insights. Emerging research suggests that cancer-specific IgM and IgG antibodies – produced by B cells upon recognizing malignant cells – could serve as stable, easily measurable blood biomarkers for detecting and monitoring high-incidence cancers like melanoma and breast, prostate, bowel, lung and pancreatic cancer. This approach has the potential to improve early diagnosis, reduce uncertainty and enhance treatment planning.
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.